Navigation Links
NeurogesX to Pursue Expanded U.S. Label for Qutenza® (capsaicin) 8% Patch in HIV-Associated Neuropathy
Date:10/18/2010

SAN MATEO, Calif., Oct. 18 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced plans to pursue a U.S. label expansion for Qutenza® (capsaicin) 8% patch to include patients with painful HIV-associated neuropathy (HIV-AN, also referred to as HIV-distal sensory polyneuropathy (HIV-DSP)).

Following a recent meeting with the U.S. Food and Drug Administration (FDA), NeurogesX plans to submit a supplemental new drug application (sNDA) in the first half of 2011.  The submission will utilize data from two completed Phase 3 studies in patients with HIV-AN.

Anthony DiTonno, President and CEO, commented, "As a company, we are focused on addressing unmet medical needs in pain and have made significant progress towards this goal with the U.S. launch of Qutenza.  Our decision to submit a supplemental NDA to address the HIV-AN patient population is important as there are currently no FDA approved treatments for HIV-AN.  U.S. label expansion to include HIV-AN would reach a new segment of neuropathic pain patients while leveraging our U.S. sales force and their relationships with pain specialists."

Qutenza is currently indicated in the U.S. for the management of neuropathic pain associated with postherpetic neuralgia (PHN), and has been evaluated in two Phase 3 studies in patients with HIV-AN. The FDA has previously granted orphan drug designation for the use of capsaicin to treat painful HIV-AN and fast track designation for Qutenza for the treatment of painful HIV-AN.

HIV-AN is thought to be caused by multiple factors related to HIV infection including injury of sensory neurons by HIV virus proteins; the immune system's fight against HIV; and some antiretroviral drugs. HIV-AN is the most common neurological complication of HIV
'/>"/>

SOURCE NeurogesX
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX to Present at J.P. Morgan Health Care Conference
2. NeurogesX to Present at Piper Jaffray Health Care Conference
3. NeurogesX Reports Third Quarter 2009 Results
4. NeurogesX to Present at Two November Conferences
5. NeurogesX to Present at UBS Global Life Sciences Conference
6. NeurogesX to Present at Upcoming Fall Conferences
7. NeurogesX Appoints New Board Director and Audit Committee Chairman
8. NeurogesX Reports Second Quarter 2009 Results
9. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
10. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
11. NeurogesX Added to Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Green & Grow Inc. (GGI) has ... and secured Otter Capital as a significant new partner. ... of GGI’s Agriplier™ technology, building on recent compelling field ... our first meeting, we have been impressed with Otter ... said Alan Sobba, President and CEO of GGI. “We ...
(Date:8/27/2014)... In 2013, Lawrence Livermore ... National Security LLC (LLNS), was awarded more ... state-of-the-art laser system for the European Union's Extreme ... in the Czech Republic. , When commissioned to ... the " High repetition-rate Advanced Petawatt Laser System ...
(Date:8/27/2014)...   MSC , a healthcare performance improvement company ... appointment of Mary Beth Loesch to President ... experience preparing companies for rapid growth and market expansion, ... of Corporate Development and Healthcare. In that role, she ... well as corporate strategy and marketing. Previously, Loesch served ...
(Date:8/27/2014)... Dallas, TX (PRWEB) August 27, 2014 ... professional and in-depth study on the current state of ... The report provides a basic overview of the industry, ... analysis and Chinese domestic market analysis are provided with ... of the market. A comparison between the international and ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2
... SAN DIEGO, Oct. 4 Orexigen® Therapeutics, Inc. (Nasdaq: ... the treatment of obesity, today announced the schedule of ... taking place at the 28th Annual Scientific Meeting of ... the San Diego Convention Center, October 8-12, 2010.Sunday, October ...
... Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today that ... Investor Forum on Wednesday, October 6 at 10:30 a.m. PDT ... Live webcasts from this conference will be available through the ... http://ir.oncogenex.com . Webcast replays will be available approximately two hours ...
... RAMAT GAN, Israel, October 4, 2010 ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
Cached Biology Technology:Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society 2OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum 2EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 2EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 3EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 4EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 5EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 6EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 7
(Date:8/27/2014)... in understanding the mysteries of the human genome was ... provide the most detailed comparison yet of how the ... , The research, appearing August 28 in in ... encoded in the three species, genomes is "read out," ... chromosomes. , The results add billions of entries to ...
(Date:8/27/2014)... N.C. -- Duke University researchers have identified a gene ... called OSCA1, encodes a protein in the cell membrane ... adjusts the plant,s water conservation machinery accordingly. , ... associate professor of biology at Duke. , The ... Nature , could make it easier to feed the ...
(Date:8/27/2014)... requires nerve cells to rearrange existing patterns of activity ... patterns, a study of monkeys has found. The scientists ... electrical activity of brain cell networks. The study was ... "We looked into the brain and may have seen ... said Aaron Batista, Ph.D., an assistant professor at the ...
Breaking Biology News(10 mins):Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4Water 'thermostat' could help engineer drought-resistant crops 2Scientists plug into a learning brain 2Scientists plug into a learning brain 3
... abnormality that appears to prevent some men from conceiving ... contraceptive, according to University of Iowa researchers reporting their ... American Journal of Human Genetics . Although ... and have proven very effective for family planning, no ...
... A major effort from within the Aspergillus community ... supplement by the Elsevier journal Fungal Genetics ... provides extensive studies based on the genome analysis ... nidulans. The publication was enabled by Eurofungbase, a ...
... student Alistair Boettiger has amassed a beautiful collection of ... them in his computer. He and George Oster, ... mathematical neuroscientist Bard Ermentrout, have written a computer program ... principles developed to explain how the brain works and ...
Cached Biology News:Gene discovery could lead to male contraceptive 2Mollusks taste memories to build shells 2Mollusks taste memories to build shells 3Mollusks taste memories to build shells 4
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
Biology Products: